Madrigal Pharmaceuticals, Inc. Common Stock Earnings Dividend

Madrigal Pharmaceuticals, Inc. Common Stock’s revenue jumped 71.17% since last year same period to $364.25Mn in the Q2 2026. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. Common Stock has generated 17% jump in its revenue since last 3-months.

Madrigal Pharmaceuticals, Inc. Common Stock’s net profit fell -37.03% since last year same period to $-57.94Mn in the Q2 2026. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. Common Stock has generated 38.62% jump in its net profits since last 3-months.

Madrigal Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 19.94% since last year same period to -15.91% in the Q2 2026. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. Common Stock has generated 47.54% jump in its net profit margins since last 3-months.

Madrigal Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -2.55 - a 38.41% jump from last quarter’s estimates.

Madrigal Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -2.55.

Madrigal Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) fell -4.74% since last year same period to -1.99 in the Q2 2026. This indicates that the Madrigal Pharmaceuticals, Inc. Common Stock has generated -4.74% annual rate of fall in its earning per share (EPS) in the last 4 quarters.